Showing results (781-790 of 802) with videos related to
Sort By:
Pageof 81
Analytical and Bioanalytical Chemistry|February 27, 2026
Effect of HDL disk and LDL dimer presence on lipoprotein particle number determination and subclassificationZsuzsanna Kuklenyik, Anna A Ivanova, Lauren E Drinkard, et al.Iscience|January 19, 2026
Mitigating increasing wildfire risk through fuel break innovationsNicholas T Link, Jill F Johnstone, Xanthe J Walker, et al.Journal of Medicinal Chemistry|January 16, 2009
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activitySteven Howard, Valerio Berdini, John A Boulstridge, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 13, 2022
The small HDL particle hypothesis of Alzheimer's diseaseAshley E Martinez, Gali Weissberger, Zsuzsanna Kuklenyik, et al.Nature Microbiology|September 27, 2022
Computational identification of a systemic antibiotic for gram-negative bacteriaRyan D Miller, Akira Iinishi, Seyed Majed Modaresi, et al.Journal of Medicinal Chemistry|July 29, 2010
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug designAndrew J Woodhead, Hayley Angove, Maria G Carr, et al.Nature Communications|March 20, 2021
Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistanceHuan Cao, Aristotelis Antonopoulos, Sadie Henderson, et al.Blood Advances|December 7, 2019
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brainAnn T Farrell, Julie Panepinto, C Patrick Carroll, et al.Trials|January 24, 2018
Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trialJo Howard, April E Slee, Simon Skene, et al.Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.Pageof 81